Navigation Links
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Date:6/17/2008

BELLEVUE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an important cell survival signaling pathway.

"PX-866 is a potent inhibitor of PI-3K, a component of a critical pathway that is activated in many types of cancer, leading to tumor growth and survival," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Oncothyreon. "We believe that the mechanism of action of PX-866, which irreversibly inhibits PI-3K, will have pharmacokinetic and pharmacodynamic advantages that will distinguish PX-866 in the competitive field of PI-3K inhibitors."

The Phase 1 trial is expected to enroll up to 63 patients with advanced metastatic cancer who have failed or are intolerant of standard therapy. Patients will receive PX-866 orally once per day on days 1 through 5 and 8 through 12 during a four-week treatment cycle. Primary objectives of the study include establishment of a maximum tolerated dose, evaluation of safety, and analysis of the pharmacodynamic and pharmacokinetic profiles of PX-866.

"The start of the PX-866 trial represents a significant milestone for Oncothyreon, as we now have three active clinical programs underway for our promising small molecule inhibitors," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "Together with our therapeutic vaccine programs, we have successfully established a broad and diverse oncology pipeline targeting multiple cancer indications with substantial unmet medical need, and we look forward to sharing the ongoing pro
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
(Date:7/30/2014)... Scottsdale, AZ (PRWEB) July 30, 2014 ... announced the launch of blended sales training programs for ... proven sales training programs used by thousands of salespeople ... Horizons' blended sales training program can be customized to ... industry. , The blended sales training program ...
(Date:7/30/2014)... July 30, 2014 Vycom announces the ... products, designed to meet Factory Mutual (FM) 4910 fire ... such as wet benches, process tools, fume hoods, furniture ... and damage to semiconductor wafers used in electronic chip ... flame-retardant PVC solution with excellent workability and superior aesthetics. ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... 25 f-star, an antibody,engineering company developing ... unique Modular Antibody Technology, today announced the,appointment ... Officer. Dr. Mudde has,over 20 years of ... in preclinical research and development. He comes ...
... Genetics Professionals Should Be Part of Genetic Testing Process Says ... American College of ... tests are,available than ever before, ranging from home DNA test ... diseases, and even home,paternity tests. Along with greater availability of ...
... Sept. 25 /PRNewswire/-- News briefs concerning the,economic and ... the Tampa Bay,Partnership: Tampa Bay Diamond Manufacturer ... Corporation recently broke ground for a planned,expansion of ... other locations, the firm decided to remain in ...
Cached Biology Technology:Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer 2Statement on Direct-To-Consumer Genetic Testing 2Statement on Direct-To-Consumer Genetic Testing 3Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3Highlights of Economic and Business Growth in the Tampa Bay Region 4
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... Brembs, professor of neurogenetics at the Institute of Zoology, ... readers and reviewers to run the underlying code within ... forward for scientific publishing, by demonstrating a completely novel ... , Figure 3 in fact doesn,t really exist. The ... F1000Research , and the figure is generated ,on the ...
(Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... are resourceful survivors with plenty of tricks for staying alive. ... lacking the tumor suppressor BRCA1 can resume one form of ... appears in the January 21 st issue of ... The BRCA1 protein helps to mend double-strand DNA breaks by ...
... to climate change could cause soils to release additional ... but that effect diminishes over the long term, finds ... Change . The study, from University of New Hampshire ... California-Davis and the Marine Biological Laboratory, sheds new light ...
... the childhood cancer neuroblastoma reinforces the challenges in ... Contrary to expectations, the scientists found relatively few ... for neuroblastoma treatment. Instead, say the researchers, they ... in response to medicine and other factors. ...
Cached Biology News:Enzyme helps cancer cells avoid genetic instability 2Enzyme helps cancer cells avoid genetic instability 3Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term 2Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term 3Tumors evolve rapidly in a childhood cancer, leaving fewer obvious tumor targets 2
NAP-2 (5C7)...
... (rapid amplification of cDNA ends) technique that ... and 3' cDNA ends. The GeneRacer Kit ... (RT) for improved amplification of the full-length ... The RNase H portion of SuperScript II ...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
Biology Products: